一种含有氯虫苯甲酰胺、莫昔克丁、吡喹酮和噻嘧啶的新型咀嚼片（Credelio Quattro™）对犬钩虫感染的治疗和控制效果。

Efficacy of a novel chewable tablet (Credelio Quattro™) containing lotilaner, moxidectin, praziquantel, and pyrantel for the treatment and control of hookworm infections in dogs.

作者信息

Charles Samuel, Deuster Katrin, Wang Xinshuo, Wiseman Scott, Reinemeyer Craig R, van der Mescht Luther, Mansour Abdelmoneim, Bouzaidi Cheikhi Imad, Young Lisa

机构信息

Elanco Animal Health, 2500 Innovation Way, Greenfield, IN, 46140, USA.

Elanco Animal Health GmbH, Alfred-Nobel-Str. 50, 40789, Monheim, Germany.

出版信息

Parasit Vectors. 2025 Apr 2;18(1):125. doi: 10.1186/s13071-025-06757-4.

DOI:10.1186/s13071-025-06757-4

PMID:40176170

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11963408/

Abstract

BACKGROUND

Hookworms, specifically Ancylostoma caninum and Uncinaria stenocephala, have a clinical impact on the health of dogs, with A. caninum posing a zoonotic risk worldwide. The studies presented here were conducted to evaluate the efficacy of a novel, oral chewable tablet (Credelio Quattro) containing lotilaner, moxidectin, praziquantel, and pyrantel (as pamoate salt) against fourth-stage larvae (L), immature adult, and adult A. caninum, as well as adult U. stenocephala, infections in dogs.

METHODS

Nine negatively controlled, masked, randomized laboratory studies evaluated the efficacy and non-interference of the drugs against various stages of A. caninum and U. stenocephala. In addition to one pilot study conducted against L A. caninum and one study that assessed efficacy in dogs with naturally acquired U. stenocephala, two experimental studies were conducted against each of the target hookworm species and stages. A total of 16-31 dogs comprised each study. With the exception of the study in dogs with naturally acquired U. stenocephala, dogs were experimentally infected with the target parasite and dosed on Day 0 or 4 with placebo tablets, Credelio Quattro tablets (or components of Credelio Quattro formulation for the pilot study), or individual actives, moxidectin or pyrantel, in the specific studies designed to assess interference. Efficacy was evaluated by comparing the number of worms recovered at necropsy 5-10 days post-treatment between the treated and control groups.

RESULTS

All dogs tolerated Credelio Quattro well. Efficacy of Credelio Quattro was ≥ 99.0% against L A. caninum, ≥ 99.8% against immature adult A. caninum, ≥ 99.9% against adult A. caninum, and ≥ 99.6% against adult U. stenocephala. Additionally, treatment with Credelio Quattro provided a ≥ 99.9% reduction in fecal egg counts 10 days post-treatment.

CONCLUSIONS

Credelio Quattro, a novel oral chewable tablet administered at the minimum effective dosages of 20 mg/kg lotilaner, 0.02 mg/kg moxidectin, 5.0 mg/kg praziquantel, and 5.0 mg/kg pyrantel (as pamoate salt), was safe and effective for the treatment and control of L, immature adult, and adult stages of A. caninum and adult U. stenocephala in dogs.

摘要

背景

钩虫，特别是犬钩口线虫和窄头钩虫，对犬类健康具有临床影响，其中犬钩口线虫在全球范围内存在人畜共患病风险。开展本研究以评估一种新型口服咀嚼片（Credelio Quattro）的疗效，该片剂含有洛替拉纳、莫昔克丁、吡喹酮和噻嘧啶（作为双羟萘酸盐），用于防治犬体内第四期幼虫、未成熟成虫和成虫阶段的犬钩口线虫感染以及成虫阶段的窄头钩虫感染。

方法

九项阴性对照、设盲、随机的实验室研究评估了该药物对犬钩口线虫和窄头钩虫各阶段的疗效及非干扰性。除了一项针对犬钩口线虫幼虫的预试验研究以及一项评估自然感染窄头钩虫的犬的疗效的研究外，针对每种目标钩虫种类和阶段均开展了两项实验研究。每项研究共有16 - 31只犬。除了针对自然感染窄头钩虫的犬的研究外，犬被实验性感染目标寄生虫，并在第0天或第4天给予安慰剂片、Credelio Quattro片（或预试验研究中Credelio Quattro制剂的成分），或在旨在评估干扰性的特定研究中给予单一活性成分莫昔克丁或噻嘧啶。通过比较治疗组和对照组在治疗后5 - 10天尸检时回收的蠕虫数量来评估疗效。

结果

所有犬对Credelio Quattro耐受性良好。Credelio Quattro对犬钩口线虫幼虫的疗效≥99.0%，对未成熟成虫的疗效≥99.8%，对成虫的疗效≥99.9%，对窄头钩虫成虫的疗效≥99.6%。此外，在治疗后10天，使用Credelio Quattro治疗使粪便虫卵计数减少≥99.9%。